Objective Valve-in-valve transcatheter aortic valve replacement (VIV TAVR) can result in
high residual gradients that are associated with increased mortality. Bioprosthetic valve …

The use of bioprosthetic prostheses during surgical aortic valve replacements has increased
dramatically over the last two decades, accounting for over 85% of surgical implantations …

The limited durability of surgical bioprostheses, combined with an ageing population, has
led to an increasing demand for replacing degenerated bioprosthetic surgical heart valves …

Structural heart disease (SHD) is an innovative field driven forward by the success of novel
transcatheter device technologies. Much of the rapid progress and expansion of this field …

Introduction: Valve-in-valve TAVR (ViV-TAVR) is an established treatment for failing surgical
aortic valves in patient at high surgical risk. Elevated transprosthetic gradients are common …

O tratamento percutâneo das valvopatias constitui tópico atual e de grande interesse na
Cardiologia. A tecnologia inovadora e excelentes resultados clínicos obtidos com o TAVI …

With the aging population, the number of patients with prosthetic aortic valves is expected to
steadily increase. Although patients in prior decades, particularly younger patients, were …

Less-invasive, transcatheter-based treatment of valvular heart disease is a topic of major
interest in cardiology nowadays. The breakthrough technology and unprecedented clinical …

Reoperative aortic valve replacement is associated with increased morbidity. Valve-in-valve
transcatheter aortic valve replacement offers a less invasive alternative to traditional …

Presentiamo il caso di un paziente di 66 anni senza fattori di rischio cardiovascolare noti né
precedenti cardiologici di rilievo, portatore di catetere vescicale a permanenza, che …